Search
GDC-0425
go.drugbank.com/drugs/DB14791Investigationalinvestigation in clinical trial NCT01359696 (A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or
Terodiline
go.drugbank.com/drugs/DB13725ExperimentalCategories: Drugs for Urinary Frequency and IncontinenceIrofulven
go.drugbank.com/drugs/DB05786InvestigationalA novel anti-cancer compound synthesized by scientists at the University of California, San Diego more than a decade ago from toxins of the poisonous jack-o-lantern mushroom, has been granted “fast track” status by the U.S. Food and Drug...
HGS-TR2J
go.drugbank.com/drugs/DB05895ExperimentalHGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.
Methyl red
go.drugbank.com/drugs/DB08209ExperimentalCategories: Compounds used in a research, industrial, or household settingNBF-006
go.drugbank.com/drugs/DB21770InvestigationalNBF-006 is under investigation in clinical trial NCT03819387 (A Study of NBF-006 in Non-small Cell Lung, Pancreatic, or Colorectal Cancer).
Cintirorgon
go.drugbank.com/drugs/DB20916InvestigationalCintirorgon is under investigation in clinical trial NCT02929862 (Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer).
Coumazoline
go.drugbank.com/drugs/DB21226ExperimentalThe usage of the INN stem '-azoline' in the name indicates that Coumazoline is a antihistaminic or local vasoconstrictor, antazoline derivative.
Domazoline
go.drugbank.com/drugs/DB19937ExperimentalThe usage of the INN stem '-azoline' in the name indicates that Domazoline is a antihistaminic or local vasoconstrictor, antazoline derivative.
Varlitinib
go.drugbank.com/drugs/DB05944InvestigationalVarlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlit...